TABLE II.
Baseline characteristics of the study patients
| Characteristic | Value |
|---|---|
| Patients (n) | 57 |
| Age (years) | |
| Median | 66 |
| Range | 43–84 |
| Sex [n (%)] | |
| Men | 33 (57.9) |
| Women | 24 (42.1) |
| White ethnicity [n (%)] | 57 (100) |
| Chemotherapy regimen [n (%)] | |
| FOLFOX | 55 (96.5) |
| XELOX | 2 (3.5) |
| Type of colorectal cancer [n (%)] | |
| Adjuvant | 29 (50.9) |
| Metastatic, non-resected | 20 (35.1) |
| Metastatic, resected | 8 (14.0) |
| Patients with comorbiditiesa [n (%)] | 15 (26.3) |
| Chronic pain | 9 (15.8) |
| Type 2 diabetes | 6 (10.5) |
| Chronic renal impairment | 3 (5.3) |
| Rheumatoid arthritis | 1 (1.8) |
| Neuropathic pain | 1 (1.8) |
| Fibromyalgia | 0 |
| Multiple sclerosis | 0 |
| Concomitant medicationsb [n (%)] | 38 (66.7) |
| Acetaminophen | 30 (52.6) |
| Opioids | 15 (26.3) |
| Antidepressantsc | 8 (14.0) |
| Anticonvulsantsd | 8 (14.0) |
| NSAIDs | 7 (12.3) |
| Topic analgesice | 5 (8.8) |
| Cannabinoidsf | 1 (1.8) |
a
Some patients had more than 1 comorbidity.
b
Some patients took more than 1 medication that could influence pain.
c
Paroxetine, citalopram, mirtazapine, nortriptyline, venlafaxine.
d
Carbamazepine, gabapentin, lamotrigine, pregabalin.
e
Lidocaine, prilocaine.
f
Nabilone.
FOLFOX = fluorouracil–leucovorin–oxaliplatin; XELOX = capecitabine–oxaliplatin; NSAIDs = nonsteroidal antiinflammatory drugs.